Macia, S, Aladid, RL, Tovar, R, Garmendia, L, Lillo, CP, Fossati, M, Romero, ML, Selles, AN, Castellano, D, Gonzalezbilla, E, Maroto-Rey, JP, Piulats, JM, Lista, AGD, Parente, P. Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.5129. PMID:. IF:41.900(Q1/1D).

Alvarez, RMA, Hindi, N, Carrasco-Garcia, I, Sanfilippo, R, Sebio, A, Redondo, A, Alvarez, A, Morosi, C, Romagosa, C, Artigas, V, Casares, CM, Asencio, JM, Guzmán-Gómez, L, González-Lopez, J, Belinchon, B, Sangalli, C, Gutierrez, A, Jurado, JC, Broto, JM, Gronchi, A. Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial-A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11507. PMID:. IF:41.900(Q1/1D).

Moura, DS, Mondaza-Hernandez, JL, Shirikova, A, Romero-Gonzalez, P, Carrera, M, Rodriguez, C, Martínez-Trufero, J, Sebio, A, Jurado, JC, Valverde, C, Beveridge, RD, Carrasco-Garcia, I, Gonzalez-Billalabeitia, E, Fernandez-Jara, J, Lopez-Jimenez, C, Hindi, N, Gutierrez, A, Broto, JM. Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23526. PMID:. IF:41.900(Q1/1D).

Gelderblom, H, Wang, V, Doherty, M, Sebio, A, Stacchiotti, S, Wilky, BA, Blay, JY, Brohl, AS, Morales, CMV, Reichardt, P, Martin-Broto, J, Davis, EJ, De Haan, JJ, O'Neill, B, Babcock, E, Garcia, J, Senne, L, Shepard, D, Chawla, SP, Jones, RL. The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11504. PMID:. IF:41.900(Q1/1D).

Ferrer, L, Nadal, E, Dejean, T, Insa, A, Menu, P, Casal, J, Domine, M, Massuti, B, Majem, M, Martinez-Marti, A, Garcia-Campelo, R, Carpeño, JD, Cobo, M, Vivanco, GL, Morillo, ED, Bernabé, R, Vinolas, N, Barneto, I, Colin, T, Provencio, M. Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8022. PMID:. IF:41.900(Q1/1D).

Pacheco-Barcia, V, Obispo, B, Tomas, E, de Torres, CS, Quintanar, T, Paez, D, Leon-Mateos, L, Cancio, H, Cortegoso, A, Anido, U, Quilez, A, Tarazona, N, Jimenez-Labaig, P, Sanchez-Martinez, DA, Goni, AS, Fernandez-Montes, A, Felip, E, Rodriguez, C, Elez, E. Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04171-x. PMID:41436708. IF:2.500(Q3/6D).

González-Lopez, J, Sebio, A, Broto, JM, Hindi, N, Villarejo-Campos, P, Jimenez, M, Díaz-Beveridge, R, Castellanos, JFO, Andajar, RL, Alvarez, RMA, Asencio, JM, Serrano, C, Conde, NR, Castro-Boix, S, Krauel, L, Colom, H, García, JAT, Lopera, E, Huguet, A, Campos, AP. First-in-human phase I study of CEB-01, a biodegradable SN-38-releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23559. PMID:. IF:41.900(Q1/1D).

Garrido, P, Villanueva, N, Bernabé, R, Campelo, RG, Sala, MA, Bote-de Cabo, H, Molla, MAI, Alvarez, R, Cruz, P, Majem, M, Santos, MAM, Cordero, MG, Rodriguez, JMO, Alvarez, RMA, Alvarez-Abril, B, Gutiérrez-Sainz, L, Gutiérrez, V, Munoz-Unceta, N, Felip, E, Isla, D. Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019-2024).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8092. PMID:. IF:41.900(Q1/1D).